ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2817

Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis

Sarah Hawtree1, Munitta Muthana1, J. Mark Wilkinson2, Anthony G. Wilson1 and Mohammed Akil3, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, 3Rheumatology Department, Sheffield South Yorkshire, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: animal models and rheumatoid arthritis, Epigenetics, Fibroblasts, histone acetylation, rheumatoid arthritis, synovium

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS) which develop a stable, auto-aggressive phenotype that augments tissue destruction. It is unknown how this phenotype is stably maintained, however epigenetic changes have been implicated. Histone acetylation is a major epigenetic mechanism (HDACs). The objective of the study is to determine the role of histone deacetylates (HDACs) in regulating the auto-aggressive phenotype of RA FLS

Methods

Real time-qPCR was used to compare levels of HDAC1-11 in RA compared with osteoarthritis (OA) FLS. Joint biopsies were co-stained with anti-HDAC1 and anti-fibroblast antibodies. HDAC1 and a non-targeting control (NTC) siRNA were transfected in vitro into RA FLS. Cell proliferation, migration and invasion after siRNA knockdown (KD) were assessed by using tritiated thymidine, a scratch assay and a matrigel invasion assay respectively. An Illumina BeadChip (47,000 transcripts) was used to analyse global gene expression changes after KD. The in vivo effect of HDAC1KD was investigated in a mouse model of collagen-induced arthritis (CIA) using in vivosiRNA. Clinical scores of CIA were measured daily (days 0-49) and the bones were analysed using a microCT scanner.

Results

The mRNA levels of HDACs 1-11 are higher in RA compared to OA FLS, with HDAC1 levels showing a 4.2-fold increase (p=0.03, n=7-10). HDAC1KD reduced FLS proliferation (p=0.04, n=6), migration (p=0.01, n=6) and invasion (p=0.02, n=6) compared to the NTC. Cluster analysis of the microarrays (n=3) revealed significant changes in genes involved in apoptosis (p≤0.009, n=21), migration (p≤0.008, n=4) and proliferation (p≤0.009, n=9). In mice with CIA, HDAC1KD significantly inhibited joint inflammation (p=0.0001, n=10) and reduced bone erosion compared to the NTC.

Conclusion

Our data implicates HDAC1 in controlling the autoaggressive phenotype of FLS in RA and our data in murine inflammatory arthritis supports targeting HDACi as a potential therapy in RA.


Disclosure:

S. Hawtree,
None;

M. Muthana,
None;

J. M. Wilkinson,
None;

A. G. Wilson,
None;

M. Akil,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histone-deacetylase-one-contributes-to-the-auto-aggressive-phenotype-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology